Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI Short-term Debt

The Short-Term Debt of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Nov 15, 2026 is 28.52 M EUR. In the previous year, Short-Term Debt was 23.69 M EUR — a change of 20.38% (higher).

Short-term Debt

28.52 MEUR

YoY

20.38%

Last updated:

Short-Term Debt of Laboratorios Farmaceuticos ROVI is 2025 28.52 M EUR. Short-Term Debt of Laboratorios Farmaceuticos ROVI was 2024 23.69 M EUR. It decreases by 20.38% higher compared to the previous year.

The Laboratorios Farmaceuticos ROVI Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
16.48 M EUR
Jan 1, 2019
12.70 M EUR
Jan 1, 2020
6.02 M EUR
Jan 1, 2021
6.40 M EUR
Jan 1, 2022
12.70 M EUR
Jan 1, 2023
13.19 M EUR
Jan 1, 2024
23.69 M EUR
Jan 1, 2025
28.52 M EUR
The Laboratorios Farmaceuticos ROVI Short-term Debt history
YEARShort-term DebtYoY
28.52 MEUR+20.38%
23.69 MEUR+79.68%
13.19 MEUR+3.84%
12.70 MEUR+98.39%
6.40 MEUR+6.28%
6.02 MEUR-52.59%
12.70 MEUR-22.91%
16.48 MEUR+1.65%
16.21 MEUR+25.00%
12.97 MEUR+27.78%
10.15 MEUR+137.41%
4.27 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Short-Term Debt of Laboratorios Farmaceuticos ROVI is 28.52 M EUR in 2025.

Short-Term Debt of Laboratorios Farmaceuticos ROVI changed from 23.69 M EUR to 28.52 M EUR, representing a 20.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Laboratorios Farmaceuticos ROVI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI